{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:46:53Z","timestamp":1777218413592,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biologicals.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:18:00Z","timestamp":1661818680000},"page":"27-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-9243","authenticated-orcid":false,"given":"Thierry","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-9062","authenticated-orcid":false,"given":"Jay","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-3105","authenticated-orcid":false,"given":"Claude","family":"Tayou Tagny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Somuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-0043","authenticated-orcid":false,"given":"W. Martin","family":"Smid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/vox.12794","article-title":"Improving haemophilia therapy in developing countries: virus-safe cryoprecipitate","volume":"114","author":"Faber","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2022.08.003_bib2","article-title":"WHO Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma","year":"2021","journal-title":"Transfus. Clin. Biol."},{"key":"10.1016\/j.biologicals.2022.08.003_bib3","article-title":"WHO Action framework to advance universal access to safe, effective and quality assured blood products","year":"2020","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.biologicals.2022.08.003_bib4","article-title":"Stepwise access to safe plasma proteins in resource-constrained countries: local production and pathways to fractionation","year":"2021","journal-title":"Vox Sang."},{"issue":"6","key":"10.1016\/j.biologicals.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/vox.13263","article-title":"Stepwise access to safe plasma proteins in resource-constrained countries: local production and pathways to fractionation-Report of an International Society of Blood Transfusion Workshop","volume":"117","author":"Burnouf","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood.2021015370","article-title":"Shortage of plasma-derived products: a looming crisis?","volume":"139","author":"Covington","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biologicals.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/vox.13267","article-title":"Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry","volume":"117","author":"Turecek","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1111\/trf.13913","article-title":"Plasma is a strategic resource","volume":"56","author":"Strengers","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2022.08.003_bib9","first-page":"449","article-title":"The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative","volume":"17","author":"Farrugia","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.biologicals.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.biologicals.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/aob.2018.05.03","article-title":"An overview of plasma fractionation","volume":"3","author":"Burnouf","year":"2018","journal-title":"Ann Blood"},{"key":"10.1016\/j.biologicals.2022.08.003_bib12","series-title":"WHO Model lists of essential Medicines WHO Model list of essential Medicines: 21st list 2019","year":"2019"},{"key":"10.1016\/j.biologicals.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17474086.2021.1957826","article-title":"Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence","volume":"14","author":"Ghosh","year":"2021","journal-title":"Expet Rev Hematol"},{"key":"10.1016\/j.biologicals.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg?","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.biologicals.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(18)30062-0","article-title":"Bitter progress in the treatment of haemophilia A in low-income countries","volume":"5","author":"Faber","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.biologicals.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biologicals.2009.01.005","article-title":"Plasma fractionation issues","volume":"37","author":"Farrugia","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2022.08.003_bib17","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1016\/S2352-3026(21)00132-0","article-title":"The case for equitable haemophilia care","volume":"8","author":"Srivastava","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.biologicals.2022.08.003_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tmrv.2019.10.005","article-title":"Selection of blood, blood components, and blood products as essential Medicines in 105 low- and middle-income countries","volume":"34","author":"Samukange","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"Suppl 4","key":"10.1016\/j.biologicals.2022.08.003_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2022.08.003_bib21","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.biologicals.2022.08.003_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","article-title":"The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality","volume":"13","author":"Rodriguez-Merchan","year":"2020","journal-title":"Expet Rev Hematol"},{"key":"10.1016\/j.biologicals.2022.08.003_bib23","first-page":"518","article-title":"Bleeding in patients with hemophilia who have inhibitors: modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements","volume":"28","author":"Alexander","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.biologicals.2022.08.003_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/10600280211049394","article-title":"Eptacog beta for bleeding treatment and prevention in congenital hemophilia A and B with inhibitors: a review of clinical data and implications for clinical practice","volume":"56","author":"Ciolek","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.biologicals.2022.08.003_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/vox.13278","article-title":"Low-dose prophylaxis and its impact on the health of haemophilia patients","volume":"117","author":"Shetty","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/hae.13753","article-title":"Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A","volume":"25","author":"Brekkan","year":"2019","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"10.1016\/j.biologicals.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hae.14552","article-title":"Low dose prophylaxis and antifibrinolytics: options to consider with proven benefits for persons with haemophilia","volume":"28","author":"Carcao","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12288-019-01147-0","article-title":"Low dose prophylaxis in hemophilia care","volume":"36","author":"Sidharthan","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.biologicals.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The world federation of hemophilia annual global survey 1999-2018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/trf.16078","article-title":"Supply and demand for plasma\u2010derived medicinal products\u2013a critical re\u2010assessment amidst the COVID\u201019 pandemic","volume":"60","author":"Hartmann","year":"2020","journal-title":"Transfusion"},{"issue":"Suppl 6","key":"10.1016\/j.biologicals.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2022.08.003_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102715","article-title":"Plasma fractionation in countries with limited infrastructure and low-\/medium income: how to move forward?","volume":"59","author":"Burnouf","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.biologicals.2022.08.003_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2471\/BLT.13.132431","article-title":"A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming","volume":"92","author":"Guti\u00e9rrez","year":"2014","journal-title":"Bull World Health Organ"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105622000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105622000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:15:19Z","timestamp":1760922919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105622000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"alternative-id":["S1045105622000471"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2022.08.003","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}